Ideaya Biosciences (IDYA) announced the submission of an investigational new drug application to the FDA for IDE892, a potential MTA-cooperative inhibitor of PRMT5. The company is targeting to begin a Phase 1 dose escalation trial of IDE892 in MTAP-deleted lung cancer in the fourth quarter of 2025, with the goal of advancing into combination trials with IDE397, Ideaya’s proprietary MAT2A inhibitor, in the first half of 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- IDEAYA Biosciences: Strategic Partnership with Servier Bolsters Financial Outlook and Validates Darovasertib Potential
- IDEAYA Biosciences: Strategic Partnerships and Financial Strength Underpin Buy Rating
- IDEAYA Biosciences Licenses Darovasertib to Servier
- Ideaya Biosciences, Servier announce exclusive darovasertib license agreement
- GSK and Ideaya’s Promising Study on Solid Tumors: A Potential Game-Changer?